Multiple Sclerosis, Primary Progressive
Conditions
Keywords
Multiple Sclerosis, Aerobic exercises, cytokine IL-10, cytokine IL-17
Brief summary
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) .It is the most common neurological disorders affecting young adults.Multiple sclerosis is an autoimmune disease that results in progressive neural degeneration. Cytokines play an important role in the pathogenesis and treatment of MS.
Detailed description
This research aims to evaluate the effect of aerobic exercises on the immune system anti-inflammatory (IL-10) and pro inflammatory (IL-17) cytokines and its consequences on the functional status in the Multiple Sclerosis patients. Aerobic exercises are a term to describe planned, structured and repetitive physical activity undertaken over a prolonged period to maintain or improve physical fitness and functional capacity .
Interventions
OTHERaerobic exercise
Sponsors
South Valley University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Double (Participant, Investigator) Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (study group) and Group B (control group),
Intervention model description
study group (GA) and control group (GB) in addition to normal matched subjects (GC).The control group (GB)was treated by the disease modifying drug (interferon beta-1a) Rebif, (GA) treated by the same drug in addition to a physical therapy program of aerobic exercises for 40 min included bicycle ergometry training
Eligibility
Sex/Gender
ALL
Age
25 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
age ranged from 25 to 45 years. All the patients were remitting relapsing MS according to (revised McDonald criteria. Duration of MS disease was one to two years before starting of the study. Last attack occurred three months ago. All patients were able to ambulate
Exclusion criteria
Patients with other neurological deficits , patient with significant orthopedic abnormalities for both lower limbs, patient with contracture , patient with deformities, pregnant females
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| blood analysis | serum anti inflammatory cytokine IL-10, will be assessed at 0 day | serum anti inflammatory cytokine IL-10, |
Countries
Egypt
Outcome results
None listed